drugset / Trial / NCT00922740

VA106483 Dose Response Study in Elderly Males

NCT00922740 ↗

Phase 1 Completed 10 enrolled Vantia Ltd
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The main purpose of the study is to evaluate the way VA106483 enters and leaves the blood and tissues over time and how the drug acts on and in the body at various dose levels compared to placebo in the same volunteer.

Timeline

Start
2009-06
Primary completion
2009-07
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject VA106483 Small molecule 4 mg —

Indications